Abstract | BACKGROUND: METHODS: The rat Yoshida AH-130 hepatoma cancer cachexia model was used in this study. Rats were treated with 4 or 40 mg/kg/d oxypurinol or placebo starting one day after tumour-inoculation for maximal 15 days. Cardiac function was analyzed by echocardiography on day 11. RESULTS: Here we show that inhibition of XO by oxypurinol significantly reduces wasting of the heart and preserves cardiac function. LVEF was higher in tumour-bearing rats treated with 4 mg/kg/d (61±4%) or 40 mg/kg/d (64±5%) oxypurinol vs placebo (51±3%, both p<0.05). Fractional shortening was improved by 4 mg/kg/d (43±3%) oxypurinol vs placebo (30±2, p<0.05), while 40 mg/kg/d oxypurinol (41±5%) did not reach statistical significance. Cardiac output was increased in the 4 mg/kg/d dose only (71±11 mL/min vs placebo 38±4 mL/min, p<0.01). CONCLUSION:
|
Authors | Jochen Springer, Anika Tschirner, Kai Hartman, Stephan von Haehling, Stefan D Anker, Wolfram Doehner |
Journal | International journal of cardiology
(Int J Cardiol)
Vol. 168
Issue 4
Pg. 3527-31
(Oct 09 2013)
ISSN: 1874-1754 [Electronic] Netherlands |
PMID | 23751350
(Publication Type: Journal Article)
|
Copyright | Copyright © 2013 Elsevier Ireland Ltd. All rights reserved. |
Chemical References |
- Xanthine Oxidase
- Oxypurinol
|
Topics |
- Animals
- Cachexia
(complications, drug therapy, enzymology)
- Cardiomyopathies
(drug therapy, enzymology, etiology)
- Liver Neoplasms
(complications, drug therapy, enzymology)
- Liver Neoplasms, Experimental
(complications, drug therapy, enzymology)
- Male
- Oxypurinol
(pharmacology, therapeutic use)
- Rats
- Rats, Wistar
- Xanthine Oxidase
(antagonists & inhibitors)
|